With every passing day, new discoveries are made that lend support to the increasing and important role biomarker analysis and tumor profiling play in personalized cancer care. Caris Life Sciences® is actively participating in research to advance the understanding of molecular science, further enabling the delivery of precision medicine.

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities

Potential actionable targets in appendiceal cancer detected by immunohistochemistry (IHC), fluorescent in situ hybridiza&on (FISH) and mutational analysis.

Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities

Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications

PD-1 and PD-L1 expression in 1599 gynecological malignancies – implications for immunotherapy

Potential actionable targets in appendiceal cancer detected by immunohistochemistry (IHC), fluorescent in situ hybridiza&on (FISH) and mutational analysis.

Machine Learning Algorithm Analysis using 55,780 Cases from a Commercial 592-gene NGS Panel to Accurately Predict Tumor Type for Carcinoma of Unknown Primary (CUP)

DNA Damage Response and Repair (DDR) Gene Mutations and Correlation with Tumor Mutation Burden (TMB) in Non-Small Cell Lung Cancer (NSCLC)

MET Exon 14 Skipping Analogs Rare but Potentially Clinically Actionable